If approved, tazbentetol could become the first Alzheimer’s therapy to target synaptic degradation.

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, researchers aren’t giving up yet.

Novo Nordisk says it still thinks GLP-1 drugs could be a promising treatment for Alzheimer’s, despite two disappointing ...

Novo Nordisk reports disappointing results from its trial of GLP-1s for Alzheimer's disease.

Semaglutide lowered inflammation, but not cognitive decline ...

An industry-focused, end-to-end meeting covering neurodegenerative R&D from early discovery through late-stage clinical and ...

A new study published on Thursday, Oct. 24, 2024, showed potentially promising results in Alzheimer's and dementia prevention: It's the third such study that indicates that semaglutides, the active ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

Sitting in plain sight. The post Scientists Intrigued by Old Drug That Reverses Signs of Alzheimer’s in Mice appeared first ...

"While semaglutide did not demonstrate efficacy in slowing the progression of Alzheimer's disease, the extensive body of ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases.

The researchers assessed the association between Alzheimer’s biomarkers and body mass index (BMI), according to a press ...